• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌患者的端粒酶活性:与预后不良及更具侵袭性的表型相关。

Telomerase activity in breast cancer patients: association with poor prognosis and more aggressive phenotype.

作者信息

Kulić Ana, Plavetić Natalija Dedić, Gamulin Stjepan, Jakić-Razumović Jasminka, Vrbanec Damir, Sirotković-Skerlev Maja

机构信息

Department of Oncology, Division of Pathophysiology and Experimental Oncology, University Hospital Center Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia.

Department of Oncology, Division of Medical Oncology, University Hospital Center Zagreb, Zagreb, Croatia.

出版信息

Med Oncol. 2016 Mar;33(3):23. doi: 10.1007/s12032-016-0736-x. Epub 2016 Jan 30.

DOI:10.1007/s12032-016-0736-x
PMID:26833480
Abstract

Telomerase expression is an important mechanism of tumor unlimited replicative potential. The aim of this study was to evaluate prognostic impact of telomerase activity in breast cancer patients and to correlate telomerase activity with established prognostic factors. We analyzed tissue of 102 malignant breast lesions and 20 healthy breast tissues. Telomerase activity was determined by telomeric repeat amplification protocol assay. Telomerase activity was present in 77 (75.49 %) of 102 breast cancers. Telomerase activity in breast cancers was statistically significantly higher in comparison with the activity in normal breast tissue. The levels of telomerase activity were significantly positively correlated with tumor size, axillary nodal status, histological grade, HER-2/neu protein expression in tumor tissue and expression of the nuclear antigen Ki-67. A statistically significant negative correlation was found between the presence of ER and telomerase activity. There was no correlation between telomerase activity and concentration of PR or the age of patients. Kaplan-Meier analysis showed that patients with higher telomerase activity had significantly shorter 10-year disease-free survival (p < 0.0001) and 10-year overall survival (p < 0.0001) than those with lower telomerase activity. These results were confirmed by logistic regression analysis. Our results support the prognostic role of telomerase activity and its relationship with the more aggressive phenotype of breast cancer.

摘要

端粒酶表达是肿瘤无限增殖潜能的重要机制。本研究旨在评估端粒酶活性对乳腺癌患者的预后影响,并将端粒酶活性与已确立的预后因素相关联。我们分析了102例乳腺恶性病变组织和20例健康乳腺组织。采用端粒重复序列扩增法检测端粒酶活性。102例乳腺癌中77例(75.49%)存在端粒酶活性。与正常乳腺组织相比,乳腺癌中端粒酶活性在统计学上显著更高。端粒酶活性水平与肿瘤大小、腋窝淋巴结状态、组织学分级、肿瘤组织中HER-2/neu蛋白表达以及核抗原Ki-67的表达呈显著正相关。雌激素受体(ER)的存在与端粒酶活性之间存在统计学上的显著负相关。端粒酶活性与孕激素受体(PR)浓度或患者年龄之间无相关性。Kaplan-Meier分析显示,端粒酶活性较高的患者10年无病生存率(p<0.0001)和10年总生存率(p<0.0001)显著低于端粒酶活性较低的患者。逻辑回归分析证实了这些结果。我们的结果支持端粒酶活性的预后作用及其与乳腺癌更具侵袭性表型的关系。

相似文献

1
Telomerase activity in breast cancer patients: association with poor prognosis and more aggressive phenotype.乳腺癌患者的端粒酶活性:与预后不良及更具侵袭性的表型相关。
Med Oncol. 2016 Mar;33(3):23. doi: 10.1007/s12032-016-0736-x. Epub 2016 Jan 30.
2
Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR.端粒酶作为乳腺癌的预后标志物:hTERT和hTR的高通量组织微阵列分析
J Pathol. 2002 Oct;198(2):181-9. doi: 10.1002/path.1191.
3
[Quantitative detection of telomerase activity and its association with clinicopathological characteristics in breast cancer].[乳腺癌中端粒酶活性的定量检测及其与临床病理特征的关系]
Ai Zheng. 2004 Sep;23(9):1041-6.
4
Telomerase activity and survival of patients with node-positive breast cancer.
J Natl Cancer Inst. 1997 Dec 17;89(24):1874-81. doi: 10.1093/jnci/89.24.1874.
5
Telomerase activity and prognosis in primary breast cancers.
J Clin Oncol. 1999 Oct;17(10):3075-81. doi: 10.1200/JCO.1999.17.10.3075.
6
Analysis of telomerase activity levels in breast cancer: positive detection at the in situ breast carcinoma stage.乳腺癌中端粒酶活性水平分析:原位乳腺癌阶段的阳性检测
Clin Cancer Res. 1997 Jan;3(1):11-6.
7
Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients.p53、bcl-2及端粒酶活性在埃及乳腺癌患者中的新作用
IUBMB Life. 2004 Aug;56(8):483-90. doi: 10.1080/15216540400010834.
8
DNA flow cytometry but not telomerase activity as predictor of disease-free survival in pT1-2/N0/G2 breast cancer.DNA流式细胞术而非端粒酶活性可作为pT1-2/N0/G2期乳腺癌无病生存期的预测指标。
Pathobiology. 2006;73(2):63-70. doi: 10.1159/000094490.
9
Quantitative determination of telomerase activity in breast cancer and benign breast diseases.乳腺癌及乳腺良性疾病中端粒酶活性的定量测定。
Neoplasma. 2001;48(4):267-73.
10
A study on telomerase activity and prognosis in breast cancer.
Med Oncol. 2003;20(2):117-26. doi: 10.1385/MO:20:2:117.

引用本文的文献

1
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics.端粒、端粒酶与癌症:作用机制、生物标志物及治疗方法
Exp Hematol Oncol. 2025 Jan 27;14(1):8. doi: 10.1186/s40164-025-00597-9.
2
Obesity-Senescence-Breast Cancer: Clinical Presentation of a Common Unfortunate Cycle.肥胖-衰老-乳腺癌:一个常见不幸循环的临床表现。
Adv Exp Med Biol. 2024;1460:821-850. doi: 10.1007/978-3-031-63657-8_27.
3
Impact of khat (Catha edulis) and oral contraceptive use on telomerase levels and tumor suppressor genes p53 and p21 in normal subjects and breast cancer patients.

本文引用的文献

1
Telomerase modulation in therapeutic approach.治疗方法中的端粒酶调节
Curr Pharm Des. 2014;20(41):6438-51. doi: 10.2174/1381612820666140630092721.
2
Extra-telomeric functions of human telomerase: cancer, mitochondria and oxidative stress.人类端粒酶的端粒外功能:癌症、线粒体与氧化应激
Curr Pharm Des. 2014;20(41):6386-403. doi: 10.2174/1381612820666140630095606.
3
Telomere maintenance mechanisms in cancer: clinical implications.癌症中的端粒维持机制:临床意义
阿拉伯茶(巧茶)和口服避孕药对正常人群和乳腺癌患者端粒酶水平及抑癌基因 p53 和 p21 的影响。
Sci Rep. 2024 Jul 16;14(1):16365. doi: 10.1038/s41598-024-67355-5.
4
OpenPBTA: The Open Pediatric Brain Tumor Atlas.开放型小儿脑肿瘤图谱:开放型儿科脑肿瘤图谱
Cell Genom. 2023 May 31;3(7):100340. doi: 10.1016/j.xgen.2023.100340. eCollection 2023 Jul 12.
5
THOR is a targetable epigenetic biomarker with clinical implications in breast cancer.THOR 是一种有靶向性的表观遗传生物标志物,对乳腺癌具有临床意义。
Clin Epigenetics. 2022 Dec 18;14(1):178. doi: 10.1186/s13148-022-01396-3.
6
DNA Methylation Analysis Identifies a Biomarker for Retinoic Acid-Induced Repression in Breast Cancer Cell Lines.DNA甲基化分析鉴定出一种乳腺癌细胞系中视黄酸诱导抑制作用的生物标志物。
Biomedicines. 2022 Mar 17;10(3):695. doi: 10.3390/biomedicines10030695.
7
Investigating the Role of Telomere and Telomerase Associated Genes and Proteins in Endometrial Cancer.探究端粒及端粒酶相关基因和蛋白质在子宫内膜癌中的作用。
Methods Protoc. 2020 Sep 3;3(3):63. doi: 10.3390/mps3030063.
8
LncRNA MEG3 inhibits non-small cell lung cancer via interaction with DKC1 protein.长链非编码RNA MEG3通过与DKC1蛋白相互作用抑制非小细胞肺癌。
Oncol Lett. 2020 Sep;20(3):2183-2190. doi: 10.3892/ol.2020.11770. Epub 2020 Jun 24.
9
Telomere Length in Renal Cell Carcinoma: The Jekyll and Hyde Biomarker of Ageing of the Kidney.肾细胞癌中的端粒长度:肾脏衰老的双面生物标志物。
Cancer Manag Res. 2020 Mar 6;12:1669-1679. doi: 10.2147/CMAR.S211225. eCollection 2020.
10
Label-Free Telomerase Activity Detection via Electrochemical Impedance Spectroscopy.通过电化学阻抗谱进行无标记端粒酶活性检测。
ACS Omega. 2019 Oct 1;4(16):16724-16732. doi: 10.1021/acsomega.9b00783. eCollection 2019 Oct 15.
Curr Pharm Des. 2014;20(41):6361-74. doi: 10.2174/1381612820666140630101047.
4
Telomerase as a useful target in cancer fighting-the breast cancer case.端粒酶作为抗癌的一个有用靶点——以乳腺癌为例。
Tumour Biol. 2013 Jun;34(3):1371-80. doi: 10.1007/s13277-013-0757-4. Epub 2013 Apr 5.
5
Regulation of the human catalytic subunit of telomerase (hTERT).端粒酶人催化亚基(hTERT)的调节。
Gene. 2012 May 1;498(2):135-46. doi: 10.1016/j.gene.2012.01.095. Epub 2012 Feb 13.
6
Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome.乳腺癌中端粒酶表达和端粒长度及其与辅助治疗和疾病结局的关系。
Breast Cancer Res. 2011 Jun 6;13(3):R56. doi: 10.1186/bcr2893.
7
High-mobility group A2 protein modulates hTERT transcription to promote tumorigenesis.高迁移率族蛋白 A2 调节端粒酶逆转录酶转录促进肿瘤发生。
Mol Cell Biol. 2011 Jul;31(13):2605-17. doi: 10.1128/MCB.05447-11. Epub 2011 May 2.
8
Hallmarks of cancer: the next generation.癌症的特征:下一代。
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
9
The potential utility of telomere-related markers for cancer diagnosis.端粒相关标志物在癌症诊断中的潜在应用。
J Cell Mol Med. 2011 Jun;15(6):1227-38. doi: 10.1111/j.1582-4934.2011.01284.x.
10
Healthy aging and disease: role for telomere biology?健康老龄化与疾病:端粒生物学的作用?
Clin Sci (Lond). 2011 May;120(10):427-40. doi: 10.1042/CS20100385.